Amedisys Inc has a consensus price target of $123.38, established from looking at the 81 latest analyst ratings. The last 3 analyst ratings were released from Raymond James, RBC Capital, and Cantor Fitzgerald on March 26, 2024, March 25, 2024, and September 14, 2023. With an average price target of $67 between Raymond James, RBC Capital, and Cantor Fitzgerald, there's an implied -27.30% downside for Amedisys Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/26/2024 | AMED | Buy Now | Amedisys | $92.16 | — | Raymond James | John Ransom | — | Maintains | Market Perform | Get Alert |
03/25/2024 | AMED | Buy Now | Amedisys | $92.16 | 8.51% | RBC Capital | Ben Hendrix | $97 → $100 | Maintains | Outperform | Get Alert |
09/14/2023 | AMED | Buy Now | Amedisys | $92.16 | 9.59% | Cantor Fitzgerald | Sarah James | $100 → $101 | Maintains | Neutral | Get Alert |
07/31/2023 | AMED | Buy Now | Amedisys | $92.16 | 9.59% | TD Cowen | Gary Taylor | $84 → $101 | Maintains | Market Perform | Get Alert |
07/27/2023 | AMED | Buy Now | Amedisys | $92.16 | 9.59% | Credit Suisse | Jonathan Yong | → $101 | Reiterates | Neutral → Neutral | Get Alert |
07/06/2023 | AMED | Buy Now | Amedisys | $92.16 | 9.59% | Jefferies | Brian Tanquilut | $98 → $101 | Downgrade | Buy → Hold | Get Alert |
06/28/2023 | AMED | Buy Now | Amedisys | $92.16 | — | Benchmark | Bill Sutherland | — | Downgrade | Buy → Hold | Get Alert |
06/27/2023 | AMED | Buy Now | Amedisys | $92.16 | — | Benchmark | Bill Sutherland | — | Downgrade | Buy → Hold | Get Alert |
06/27/2023 | AMED | Buy Now | Amedisys | $92.16 | 9.59% | Truist Securities | David Macdonald | $97 → $101 | Maintains | Hold | Get Alert |
06/07/2023 | AMED | Buy Now | Amedisys | $92.16 | 5.25% | Truist Securities | David Macdonald | → $97 | Downgrade | Buy → Hold | Get Alert |
06/06/2023 | AMED | Buy Now | Amedisys | $92.16 | 8.51% | Cantor Fitzgerald | Sarah James | $91 → $100 | Maintains | Neutral | Get Alert |
06/06/2023 | AMED | Buy Now | Amedisys | $92.16 | 24.78% | Benchmark | Bill Sutherland | → $115 | Reiterates | Buy → Buy | Get Alert |
06/06/2023 | AMED | Buy Now | Amedisys | $92.16 | 8.51% | Credit Suisse | Jonathan Yong | $115 → $100 | Downgrade | Outperform → Neutral | Get Alert |
05/08/2023 | AMED | Buy Now | Amedisys | $92.16 | -8.85% | TD Cowen | Gary Taylor | $95 → $84 | Maintains | Market Perform | Get Alert |
05/05/2023 | AMED | Buy Now | Amedisys | $92.16 | -4.51% | Barclays | Steve Valiquette | $93 → $88 | Maintains | Equal-Weight | Get Alert |
05/04/2023 | AMED | Buy Now | Amedisys | $92.16 | 5.25% | Truist Securities | David Macdonald | $115 → $97 | Maintains | Buy | Get Alert |
05/04/2023 | AMED | Buy Now | Amedisys | $92.16 | 11.76% | Stephens & Co. | Scott Fidel | → $103 | Reiterates | → Equal-Weight | Get Alert |
04/21/2023 | AMED | Buy Now | Amedisys | $92.16 | -5.6% | Cantor Fitzgerald | Sarah James | → $87 | Initiates | → Neutral | Get Alert |
04/13/2023 | AMED | Buy Now | Amedisys | $92.16 | 24.78% | Truist Securities | David Macdonald | $130 → $115 | Maintains | Buy | Get Alert |
The latest price target for Amedisys (NASDAQ: AMED) was reported by Raymond James on March 26, 2024. The analyst firm set a price target for $0.00 expecting AMED to fall to within 12 months (a possible -100.00% downside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Amedisys (NASDAQ: AMED) was provided by Raymond James, and Amedisys maintained their market perform rating.
The last upgrade for Amedisys Inc happened on March 1, 2022 when UBS raised their price target to $168. UBS previously had a sell for Amedisys Inc.
The last downgrade for Amedisys Inc happened on July 6, 2023 when Jefferies changed their price target from $98 to $101 for Amedisys Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.
While ratings are subjective and will change, the latest Amedisys (AMED) rating was a maintained with a price target of $0.00 to $0.00. The current price Amedisys (AMED) is trading at is $92.16, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.